



CEOs and R&D managers use BMSystems to launch “Fully External B plans” to de-risk their business and generate unexpected opportunities.

Paris, France – February 24, 2017: *Bio-Modeling Systems* (BMSystems). With **90.4%** failure rate in R&D development and, according to Stanford University, **85%** of research resources being wasted due to exaggerations and frauds, R&D managers and CEOs already launched “Fully External R&D B plans”, giving real and fair opportunities to clearly high potential non-dominant thinking to de-risk their businesses and generate truly novel integrated solutions for patients. They *are fully convinced there is a solution!*

Bio-Modeling Systems, is one of these few “fast-growing minority thinking” who has already proven that this is possible.

BMSystems, created in 2004 and profitable since 2006, thanks to our recurrent clients, is the world's first Mechanisms-Based Medicine company that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data. Our work already led to:

1. *A world's first in neurodegenerative diseases (publication) with 2 awards in the US and Europe.*
2. *Pherecydes-Pharma: BMSystems' spin-off, MR infections therapies, publication, in Phase I/II,*
3. Our high impact “*robust decision-making*” support, to answer the unacceptable *clinical failure rate of 90%-95%* for CEOs, R&D, Business Managers & Investors
4. Our Digital R&D, and E health “transformation” expertise to help and support our clients/partners to understand *the real potential and limits of the digital giants promises* in discovery and implement their programs with the right concepts and tools.

In-licensing new diagnostics or treatments is a priority for Pharma companies, but with a **90.4%** failure rate making the right decision as soon as possible becomes critical to save time and money.

We propose to our clients/partners a robust decision making support for their R&D and Business:

1. *GO-NO GO decision before product acquisition or for portfolio risk analysis.*
2. *GO-NO GO decision before next development phase.*
3. *R&D program Rescue for a program facing critical issues during its lifetime.*
4. *Fully External R&D B plan program when the A plan cannot be rescued to discover novel diagnostics & therapies.*
5. *Exploratory Discovery program to generate novel causal mechanism concepts and discover novel diagnostics & therapies.*

We warmly invite you to download our *Short Presentation (recommended)* or our *Full Presentation with the working principles and the 10 POCs exposed in detail.*

Do not hesitate [to contact us](#)

Best regards,

Manuel GEA CEO and François IRIS CSO
Bio-Modeling Systems

For more information: www.bmsystems.net

Author's LinkedIn Posts: <https://www.linkedin.com/today/posts/manuelgea>

I should be very happy if you accept to join my networks

- <https://www.linkedin.com/in/manuelgea>
- <https://twitter.com/manuelgea>